Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sotorasib

FDA-approved product (tablet, oral), marketed as Lumakras.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Sotorasib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis71.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sotorasib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sotorasib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

    NCT05054725 · start 2021-12-30

    Registered record
    Registry ID
    NCT05054725
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    RMC-4630; Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-12-30
    Completion
    2024-08-29
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionRMC-4630; Sotorasib
    PhasePhase 2
    Registry statusCompleted

  • A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

    NCT05036291 · start 2021-10-01

    Registered record
    Registry ID
    NCT05036291
    Conditions
    Advanced Solid Tumor
    Interventions
    NB004 tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2021-10-01
    Completion
    2025-10-10
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor
    InterventionNB004 tablets
    PhasePhase 1
    Registry statusTerminated

  • A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

    NCT04959981 · start 2021-09-02

    Registered record
    Registry ID
    NCT04959981
    Conditions
    Advanced Non-squamous Non-small-cell Lung Cancer
    Interventions
    ERAS-007; ERAS-601; Osimertinib; Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-09-02
    Completion
    2023-04-27
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Non-squamous Non-small-cell Lung Cancer
    InterventionERAS-007; ERAS-601; Osimertinib; Sotorasib
    PhasePhase 1
    Registry statusCompleted

  • Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

    NCT05045638 · start 2021-08-20

    Registered record
    Registry ID
    NCT05045638
    Conditions
    Healthy Participants
    Interventions
    Rosuvastatin; Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-08-20
    Completion
    2021-10-10
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionRosuvastatin; Sotorasib
    PhasePhase 1
    Registry statusCompleted

  • A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy Participants

    NCT05048784 · start 2021-08-16

    Registered record
    Registry ID
    NCT05048784
    Conditions
    Healthy Participants
    Interventions
    Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-08-16
    Completion
    2022-02-18
    Enrolment
    145

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionSotorasib
    PhasePhase 1
    Registry statusCompleted

  • Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

    NCT04892017 · start 2021-06-15

    Registered record
    Registry ID
    NCT04892017
    Conditions
    Non-Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Solid Tumor
    Interventions
    Inlexisertib; Trametinib; Binimetinib; Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2021-06-15
    Completion
    2026-03-30
    Enrolment
    91

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Solid Tumor
    InterventionInlexisertib; Trametinib; Binimetinib; Sotorasib
    PhasePhase 1
    Registry statusTerminated

  • Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment

    NCT04887064 · start 2021-04-22

    Registered record
    Registry ID
    NCT04887064
    Conditions
    Hepatic Impairment
    Interventions
    Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-04-22
    Completion
    2022-03-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    InterventionSotorasib
    PhasePhase 1
    Registry statusCompleted

  • Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

    NCT04625647 · start 2021-04-16

    Registered record
    Registry ID
    NCT04625647
    Conditions
    Lung Adenocarcinoma; Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    Interventions
    Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-04-16
    Completion
    2027-12-31
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Adenocarcinoma; Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8 +2 more
    InterventionSotorasib
    PhasePhase 2
    Registry statusActive not recruiting

  • JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

    NCT04720976 · start 2021-03-23

    Registered record
    Registry ID
    NCT04720976
    Conditions
    Solid Tumor; NSCLC
    Interventions
    JAB-3312; Binimetinib; Pembrolizumab; Sotorasib; Osimertinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2021-03-23
    Completion
    2023-12-19
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor; NSCLC
    InterventionJAB-3312; Binimetinib; Pembrolizumab; Sotorasib +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

    NCT04303780 · start 2020-06-04

    Registered record
    Registry ID
    NCT04303780
    Conditions
    KRAS p, G12c Mutated /Advanced Metastatic NSCLC
    Interventions
    AMG 510; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-06-04
    Completion
    2026-06-24
    Enrolment
    345

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKRAS p, G12c Mutated /Advanced Metastatic NSCLC
    InterventionAMG 510; Docetaxel
    PhasePhase 3
    Registry statusCompleted

  • AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

    NCT04380753 · start 2020-04-28

    Registered record
    Registry ID
    NCT04380753
    Conditions
    Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
    Interventions
    AMG 510
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-04-28
    Completion
    2026-02-09
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
    InterventionAMG 510
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Participants

    NCT05571163 · start 2020-03-06

    Registered record
    Registry ID
    NCT05571163
    Conditions
    Healthy Participants
    Interventions
    AMG 510
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-03-06
    Completion
    2020-06-14
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionAMG 510
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

    NCT05581992 · start 2020-01-06

    Registered record
    Registry ID
    NCT05581992
    Conditions
    Healthy Participants
    Interventions
    AMG 510; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-06
    Completion
    2020-01-26
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionAMG 510; Omeprazole
    PhasePhase 1
    Registry statusCompleted

  • Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

    NCT04185883 · start 2019-12-17

    Registered record
    Registry ID
    NCT04185883
    Conditions
    Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation
    Interventions
    Sotorasib; Trametinib; RMC-4630; Afatinib; Pembrolizumab; Panitumumab; Carboplatin, pemetrexed, docetaxel, paclitaxel; Atezolizumab; Palbociclib; MVASI® (bevacizumab-awwb); TNO155; IV Chemotherapy (Regimen 1); IV Chemotherapy (Regimen 2); BI 1701963; AMG 404; Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2019-12-17
    Completion
    2027-12-05
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation
    InterventionSotorasib; Trametinib; RMC-4630; Afatinib +12 more
    PhasePhase 1
    Registry statusActive not recruiting

  • A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

    NCT05581758 · start 2019-11-14

    Registered record
    Registry ID
    NCT05581758
    Conditions
    Healthy Participants
    Interventions
    AMG 510
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-11-14
    Completion
    2019-12-09
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionAMG 510
    PhasePhase 1
    Registry statusCompleted